Anderson F L, Jubiz W, Tsagaris T J
Am J Physiol. 1976 Aug;231(2):426-9. doi: 10.1152/ajplegacy.1976.231.2.426.
Degradation of prostaglandin E2 (PGE2) and F2 alpha (PGF2 alpha) by the liver was determined in 16 dogs. PGE2 (8 dogs) or PGF2 alpha (8 dogs) was infused into the left ventricle at rates of 3.75, 7.5, 15, 37.5, and 75 mug/min. Blood samples obtained simultaneously from the portal vein (PV), hepatic vein (HV), and abdominal inferior vena cava (IVC) at each infusion rate were tested for PGE or PGF concentration by radioimmunoassy. During PGE2 infusion the mean PGE concentrations in the PV were 0.60, 1.05, 1.40, 2.29, 4.80, and 7.29 ng/ml at each infusion rate, Corresponding concentrations in the HV were 0.51, 0.62, 0.71, 0.96, 1.94, and 2.62 ng/ml, and in the IVC 0.51, 0.95, 1.31, 1.96, 4.31, AND 5;18 NG/ML. During PGF2 alpha infusion, the mean PGF concentrations in the PV were 0.32, 0.59, 0.73, 1.73, 4.11, and 7.11 ng/ml at the respective infusion rates; Corresponding concentrations in the HV were 0.26, 0.24, 0.33, 0.48, 0.49, and 0.96 ng/ml, and in the IVC 0.32, 0.50, 0.61, 1.10, 2.40, and 4.17 ng/ml. Thus, these data indicate that the canine liver has substantial, but not unlimited, capacity for degradation of PGE2 and PGF2 alpha in the portal circulation. Whether or not PGE or PGF levels in the PV may exceed this capacity during periods of stress or whether this enzymatic mechanism may be suppressed by either physiological or pharmacological factors is not known.
在16只犬中测定了肝脏对前列腺素E2(PGE2)和前列腺素F2α(PGF2α)的降解情况。将PGE2(8只犬)或PGF2α(8只犬)以3.75、7.5、15、37.5和75微克/分钟的速率注入左心室。在每个注入速率下,同时从门静脉(PV)、肝静脉(HV)和腹下腔静脉(IVC)采集血样,通过放射免疫分析检测PGE或PGF的浓度。在注入PGE2期间,每个注入速率下PV中的平均PGE浓度分别为0.60、1.05、1.40、2.29、4.80和7.29纳克/毫升,HV中的相应浓度分别为0.51、0.62、0.71、0.96、1.94和2.62纳克/毫升,IVC中的浓度分别为0.51、0.95、1.31、1.96、4.31和5.18纳克/毫升。在注入PGF2α期间,相应注入速率下PV中的平均PGF浓度分别为0.32、0.59、0.73、1.73、4.11和7.11纳克/毫升;HV中的相应浓度分别为0.26、0.24、0.33、0.48、0.49和0.96纳克/毫升,IVC中的浓度分别为0.32、0.50、0.61、1.10、2.40和4.17纳克/毫升。因此,这些数据表明犬肝脏在门静脉循环中对PGE2和PGF2α具有相当大但并非无限的降解能力。在应激期间PV中的PGE或PGF水平是否会超过这种能力,或者这种酶促机制是否会被生理或药理因素抑制,目前尚不清楚。